Todd C. Davis - 11 Jun 2026 Form 4 Insider Report for Pelthos Therapeutics Inc. (PTHS)

Reporting relationship: Director
Issuer ticker: PTHS
Reported as of: 11 Jun 2026
Net transaction value: +$999,983
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:25:26 UTC
Prior SEC filing: 12 Jun 2026
Next SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John M. Gay, by power of attorney

Key filing fact

Todd C. Davis filed Form 4 for Pelthos Therapeutics Inc. (PTHS) on 15 Jun 2026.

Key facts

This page summarizes Todd C. Davis's Form 4 filing for Pelthos Therapeutics Inc. (PTHS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 17:25.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: +$999,983.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001392029 Primary reporting owner

Davis Todd C

Relationship: Director
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ John M. Gay, by power of attorney
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTHS transaction

Common Stock

Purchase

Transaction value: $985,534
Shares: +35,445
Change %: +89%
Price: $27.80
Shares after: 75,331
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

PTHS transaction

Common Stock

Purchase

Transaction value: $14,449
Shares: +503
Change %: +0.67%
Price: $28.73
Shares after: 75,834
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F2

PTHS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,500,000
Date: 11 Jun 2026
Ownership: By Ligand Pharmaceuticals Incorporated
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F3

Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.